Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer

Impact · against what's priced in

Arbutus Biopharma is introducing a significant catalyst through a $230 million share repurchase program, providing a concrete valuation floor of $5.00 to $5.75. While the ongoing litigation against Pfizer and BioNTech is a known factor, the direct return of capital from the Moderna settlement creates immediate upward pressure on ABUS shares.

ABUS+0.80

No priced-in read yet